Log in

Anchiano Therapeutics Stock Forecast, Price & News

+0.07 (+4.67 %)
(As of 11/25/2020 12:00 AM ET)
Today's Range
Now: $1.57
50-Day Range
MA: $1.26
52-Week Range
Now: $1.57
Volume113,097 shs
Average Volume171,690 shs
Market Capitalization$11.65 million
P/E Ratio10.47
Dividend YieldN/A
Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.75 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ANCN



Sales & Book Value

Annual SalesN/A
Book Value$0.72 per share


Net Income$-27,120,000.00


Market Cap$11.65 million
Next Earnings Date3/16/2021 (Estimated)
OptionableNot Optionable
+0.07 (+4.67 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANCN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Anchiano Therapeutics (NASDAQ:ANCN) Frequently Asked Questions

How has Anchiano Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Anchiano Therapeutics' stock was trading at $0.8191 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ANCN shares have increased by 91.7% and is now trading at $1.57.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than Anchiano Therapeutics?

Wall Street analysts have given Anchiano Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Anchiano Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Anchiano Therapeutics' next earnings date?

Anchiano Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 16th 2021.
View our earnings forecast for Anchiano Therapeutics

How were Anchiano Therapeutics' earnings last quarter?

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) announced its quarterly earnings data on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.12.
View Anchiano Therapeutics' earnings history

Are investors shorting Anchiano Therapeutics?

Anchiano Therapeutics saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 60,100 shares, an increase of 526.0% from the October 15th total of 9,600 shares. Based on an average trading volume of 444,100 shares, the days-to-cover ratio is presently 0.1 days.
View Anchiano Therapeutics' Short Interest

Who are some of Anchiano Therapeutics' key competitors?

What other stocks do shareholders of Anchiano Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anchiano Therapeutics investors own include AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Abeona Therapeutics (ABEO), Aurora Cannabis (ACB), Achieve Life Sciences (ACHV), Acorda Therapeutics (ACOR), Acasti Pharma (ACST), Aduro Biotech (ADRO) and AnaptysBio (ANAB).

Who are Anchiano Therapeutics' key executives?

Anchiano Therapeutics' management team includes the following people:
  • Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 54, Pay $352k)
  • Mr. Neil H. Cohen, CEO & Director (Age 57)
  • Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 82)
  • Mr. Andrew Fine, Chief Financial Officer (Age 50)
  • Mr. Salar Roshan, VP & Head of Bus. Devel. (Age 37)
  • Mr. Avraham Hampel M.B.A., Deputy CFO & Company Sec.
  • Mr. Or Dolev, Controller (Age 42)

When did Anchiano Therapeutics IPO?

(ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is Anchiano Therapeutics' stock symbol?

Anchiano Therapeutics trades on the NASDAQ under the ticker symbol "ANCN."

How do I buy shares of Anchiano Therapeutics?

Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Anchiano Therapeutics' stock price today?

One share of ANCN stock can currently be purchased for approximately $1.57.

How big of a company is Anchiano Therapeutics?

Anchiano Therapeutics has a market capitalization of $11.65 million. The company earns $-27,120,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. Anchiano Therapeutics employs 16 workers across the globe.

What is Anchiano Therapeutics' official website?

The official website for Anchiano Therapeutics is www.anchiano.com.

How can I contact Anchiano Therapeutics?

Anchiano Therapeutics' mailing address is ONE KENDALL SQUARE BUILDING 400 SUITE 14-105, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-4622 or via email at [email protected]

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.